FDA Approves Rare Kidney Disease Drug Despite Trial Missing Kidney Function Goal

Why Did the FDA Approve a Drug That Failed Its Main Trial Goal?

The FDA's accelerated approval framework allows drugs for serious conditions to reach patients based on surrogate endpoints — laboratory measures thought to predict clinical benefit — rather than direct evidence of improved outcomes. In this case, the drug met earlier targets for reducing proteinuria, the leakage of protein into urine that typically signals kidney damage. Regulators accepted this marker as a reasonable predictor of slower kidney decline, even though the confirmatory trial did not show a statistically convincing improvement in estimated glomerular filtration rate (eGFR), the standard measure of kidney function.

Critics argue the approval highlights a persistent weakness in the accelerated approval system, originally designed in the HIV era to speed lifesaving therapies. When confirmatory trials fail to verify clinical benefit, regulators face difficult choices: withdraw the drug and remove an option from patients with few alternatives, or keep it on the market while demanding additional evidence. For rare kidney diseases with limited treatment options, the FDA has historically leaned toward preserving access, a stance that patient groups support but some outside advisors have challenged.

What Does This Mean for Patients With Rare Kidney Diseases?

Rare kidney diseases such as focal segmental glomerulosclerosis (FSGS) and IgA nephropathy affect small patient populations but can progress to end-stage kidney disease requiring dialysis or transplantation. For many of these conditions, effective disease-modifying therapies remain scarce. A drug that reduces proteinuria may still slow damage to the kidney's filtering units even if the trial design, patient numbers, or follow-up duration were insufficient to detect a clear eGFR signal.

Nephrologists will likely continue prescribing the therapy while monitoring kidney function carefully and using shared decision-making with patients. The episode reinforces a broader conversation within the nephrology community about designing better trials for rare kidney diseases, including longer follow-up, adaptive designs, and biomarker panels that more reliably predict long-term outcomes than proteinuria alone.

How Common Is FDA Approval After a Failed Confirmatory Trial?

The FDA has repeatedly faced criticism when confirmatory trials for accelerated-approval drugs miss their endpoints, particularly in oncology and rare diseases. Independent advisory committees, Congress, and outside researchers have called for tighter timelines on confirmatory studies and clearer procedures for withdrawal when evidence does not materialize. The agency has taken steps in recent years to require confirmatory trials be underway at the time of accelerated approval, but outcomes still vary.

For clinicians and patients, the practical takeaway is that accelerated approval should not be read as equivalent to full approval backed by outcome data. Transparent discussion of the evidence — including what the trial did and did not show — helps patients make informed choices. For the broader drug-development ecosystem, such decisions signal that surrogate endpoints remain central to rare disease approvals, while also putting pressure on sponsors to design confirmatory trials robust enough to deliver definitive answers.